文献速递泌尿男性生殖肿瘤

局限期前列腺癌超大分割对比常规分割放疗10年随访结果

Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.
PubMed 文献 · Lancet Oncol · 2026-02-05

HYPO-RT-PC研究是一项开放标签、随机、3期非劣效性试验,纳入1200例中高危局限期前列腺癌患者,比较超大分割放疗(42·7 Gy/7次)与常规分割放疗(78·0 Gy/39次)。中位随访约10·6-10·7年后,10年无失败生存率分别为72%与65%,校正HR 0·84(95%CI 0·69-1·03),证实非劣效性,两组晚期≥2级泌尿及胃肠毒性相似。

要点

  • 超大分割放疗10年无失败生存非劣于常规分割,校正HR 0·84(95%CI 0·69-1·03)。
  • 两组晚期≥2级泌尿毒性分别为28%与30%,胃肠毒性均为14%。
  • 7次超大分割方案可作为中危局限期前列腺癌安全有效的标准治疗选择。

核心结论

  • 10年随访证实超大分割放疗对比常规分割放疗具有非劣效性,且毒性谱相似。

研究设计与样本

  • 开放标签、随机、3期非劣效性试验,在瑞典10个中心和丹麦2个中心开展。
  • 纳入≤75岁、中危或高危局限期前列腺癌、WHO体能状态0-2、未使用过雄激素剥夺治疗的患者。
  • 1200例随机1:1分组,1180例构成符合方案人群(常规分割591例、超大分割589例)。

主要发现

  • 中位随访常规分割组10·6年(IQR 9·0-13·0)、超大分割组10·7年(IQR 9·1-12·7)。
  • 10年无失败生存率常规分割组65%(95%CI 61-69)、超大分割组72%(95%CI 68-76)。
  • 主要终点校正HR 0·84(95%CI 0·69-1·03),证实非劣效性。

关键数值与推荐

  • 超大分割方案为42·7 Gy分7次、每周3天、共2·5周;常规分割为78·0 Gy分39次、每周5天、共8周。
  • 主要终点无失败生存定义为至生化失败、临床进展、启动雄激素剥夺治疗或前列腺癌死亡的首个事件。
  • 非劣效界值为5年4%,对应HR临界上限1·338。
  • 晚期≥2级泌尿毒性:常规分割30%(95%CI 26-34) vs 超大分割28%(95%CI 24-32),HR 1·01(95%CI 0·81-1·25;p=0·95)。
  • 晚期≥2级胃肠毒性:常规分割14%(95%CI 11-18) vs 超大分割14%(95%CI 11-17),HR 0·94(95%CI 0·70-1·28;p=0·72)。

临床怎么用

  • 7次超大分割放疗可作为中危局限期前列腺癌安全、有效且实用的标准治疗选项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HYPO-RT-PC is a phase 3 trial comparing ultra-hypofractionated and conventionally fractionated radiotherapy in intermediate-to-high-risk localised prostate cancer. This 10-year update reports long-term efficacy and toxicity outcomes. METHODS: In this open-label, randomised, phase 3, non-inferiority trial done in ten centres in Sweden and two in Denmark, we recruited men aged 75 years or younger with intermediate-risk or high-risk prostate cancer and a WHO performance status between 0 and 2. Previous or current androgen deprivation therapy was not permitted. Patients were randomly assigned (1:1) to ultra-hypofractionated radiotherapy (42·7 Gy in seven fractions, 3 days per week for 2·5 weeks) or conventionally fractionated radiotherapy (78·0 Gy in 39 fractions, 5 days per week for 8 weeks). Randomisation was performed with a minimisation algorithm balancing T stage, Gleason score, prostate-specific antigen, and trial centre. The primary endpoint was failure-free survival, defined as time from randomisation to the first occurrence of biochemical failure, evidence of clinical progression, initiation of androgen deprivation therapy, or death from prostate cancer, analysed in the per-protocol population. The non-inferiority margin was 4% at 5 years and had previously been met, corresponding to a critical hazard ratio (HR) limit of 1·338. Toxicity was assessed using the Radiation Therapy Oncology Group morbidity scale. Here, we report long-term efficacy and safety results at 10 years. The trial is registered with the ISRCTN registry, ISRCTN45905321, and is closed. FINDINGS: Between July 1, 2005, and Nov 4, 2015, 1200 patients were randomly assigned to conventional fractionated radiotherapy (n=602) or ultra-hypofractionated radiotherapy (n=598). Ten patients withdrew consent, eight were found to be ineligible, and two died of reasons unrelated to prostate cancer. 1180 patients constituted the per-protocol population (591 in the conventional fractionation group and 589 in the ultra-hypofractionation group). After a median follow-up of 10·6 years (IQR 9·0-13·0) in the conventional fractionation group and 10·7 years (9·1-12·7) in the ultra-hypofractionation group, 205 and 178 primary events were observed, respectively. 10-year failure-free survival was 65% (95% CI 61-69) in the conventionally fractionated group and 72% (68-76) in the ultra-hypofractionated group. The adjusted HR for the primary endpoint was 0·84 (95% CI 0·69-1·03; Cox regression analysis), confirming non-inferiority. The 10-year cumulative incidence of late grade 2 or worse genitourinary toxic effects was 30% (95% CI 26-34) in the conventional fractionation group and 28% (24-32) in the ultra-hypofractionated group (HR 1·01, 95% CI 0·81-1·25; p=0·95). For late grade 2 or worse gastrointestinal toxic effects, the corresponding figures were 14% (95% CI 11-18) and 14% (11-17; HR 0·94, 95% CI 0·70-1·28; p=0·72). INTERPRETATION: This 10-year follow-up confirms the non-inferiority of the ultra-hypofractionated radiotherapy regimen compared with the conventionally fractionated, with similar toxicity profiles. The findings support the seven-fraction schedule as a safe, effective, and practical standard-of-care option for patients with intermediate-risk prostate cancer. FUNDING: The Nordic Cancer Union, the Swedish Cancer Society, the Swedish Research Council, the Swedish Prostate Cancer Association, and Cancerforskningsfonden i Norrland.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Nilsson P, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2026. PMID: 41655576. doi:10.1016/S1470-2045(25)00656-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。